In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Orphaning Biotech? The Impact of Biosimilars on Biotech Investment

Executive Summary

An abbreviated follow-on biologics pathway is inevitable, despite the fact that Congress failed to pass legislation in 2007. Will a FOBs pathway adversely impact money flowing into the biotech industry? Unlikely. The impact of the 1983 Orphan Drug Act may be a good model to consider. (This article first appeared in the RPM Report, January 2008).
Advertisement

Related Content

Turning Back the Clock: Drug Approvals Hit 25 Year Low
No Roferon for You! Another Way for Biotech to Play FOBs Defense?
Genzyme: Why Diversification is Starting to Look Smart
Genzyme: Why Diversification is Starting to Look Smart
Flubbing the FOBs Opportunity: Follow-on Biologics Winners & Losers
Finding a Way Out of Pharma's Dealmaking Dilemma
Finding a Way Out of Pharma's Dealmaking Dilemma
Vaccines Enter the New Age of Adjuvants

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV003067

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel